Insider · CIK 0001875714
Steven Pieper
Files at XERS (Xeris Biopharma Holdings, Inc.). First filing Nov 21, 2023, latest Oct 2, 2026.
In brief
Steven Pieper files SEC Form 4 as officer at XERS (Xeris Biopharma Holdings, Inc.). Since Nov 21, 2023, Steven Pieper has reported 1 open-market buy worth $55k and 4 open-market sells worth $515k, the latest filed on Oct 2, 2026.
A track record needs three past buys with six months of prices behind them; Steven Pieper has 0, so none is measured yet.
The newest scored trade: sold $47k of XERS on Oct 1, 2026, filed Oct 2, 2026, scored 16 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 4 sells worth $515k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
XERS: Xeris Biopharma Holdings, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 16Weak | Xeris Biopharma Holdings, Inc. | $47k 5,000 shares | -0% | +75% from low-7% from high | |
| 16Weak | Xeris Biopharma Holdings, Inc. | $43k 5,000 shares | -0% | - | |
| 16Weak | Xeris Biopharma Holdings, Inc. | $43k 5,000 shares | -0% | +60% from low-14% from high | |
| 26Weak | Xeris Biopharma Holdings, Inc. | $383k 45,000 shares | -3% | +78% from low-15% from high | |
| 45Moderate | Xeris Biopharma Holdings, Inc. | $55k 28,000 shares | +2% | +77% from low-39% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 12, 2026 | XERS XERIS BIOPHARMA HOLDINGS INC | 20,000 0.01% of outstanding | $168k | Aug 12, 2026 | $383k |
| Jul 7, 2026 | XERS XERIS BIOPHARMA HOLDINGS, INC. | 27,600 0.02% of outstanding | $231k | Jul 7, 2026 | $148k |
| Jul 6, 2026 | XERS XERIS BIOPHARMA HOLDINGS, INC. | 17,400 0.01% of outstanding | $144k | Jul 6, 2026 | none |
Transactions
Every row this insider has filed, 19 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -5,000 | $9.41 | $47k | 1,351,053 | 12 d ago |
| Sep 1, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -5,000 | $8.50 | $43k | 1,356,053 | 43 d ago |
| Aug 12, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -5,000 | $8.50 | $43k | 1,361,053 | Aug 12, 2026 |
| Jul 6, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -17,400 | $8.50 | $148k | 1,393,653 | Jul 7, 2026 |
| Jul 7, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -27,600 | $8.52 | $235k | 1,366,053 | Jul 7, 2026 |
| Mar 5, 2026 | XERS Xeris Biopharma Holdings, Inc. | MOption exercise Common Stock | +27,891 | $4.09 | $114k | 1,394,904 | Mar 5, 2026 |
| Mar 5, 2026 | XERS Xeris Biopharma Holdings, Inc. | MOption exercise Common Stock | +14,036 | $5.93 | $83k | 1,408,940 | Mar 5, 2026 |
| Mar 5, 2026 | XERS Xeris Biopharma Holdings, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -27,891 | $0.00 | $0 | 0 | Mar 5, 2026 |
| Mar 5, 2026 | XERS Xeris Biopharma Holdings, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -14,036 | $0.00 | $0 | 0 | Mar 5, 2026 |
| Jan 30, 2026 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Common Stock | +154,986 | $0.00 | $0 | 1,572,547 | Feb 2, 2026 |
| Jan 31, 2026 | XERS Xeris Biopharma Holdings, Inc. | FTax withholding Common Stock | -111,765 | $7.36 | $823k | 1,460,782 | Feb 2, 2026 |
| Jan 31, 2026 | XERS Xeris Biopharma Holdings, Inc. | FTax withholding Common Stock | -66,450 | $7.36 | $489k | 1,394,332 | Feb 2, 2026 |
| Jan 31, 2026 | XERS Xeris Biopharma Holdings, Inc. | FTax withholding Common Stock | -27,319 | $7.36 | $201k | 1,367,013 | Feb 2, 2026 |
| Jan 30, 2026 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +207,207 | $0.00 | $0 | 207,207 | Feb 2, 2026 |
| Nov 22, 2024 | XERS Xeris Biopharma Holdings, Inc. | MOption exercise Common Stock | +19,483 | $1.55 | $30k | 1,441,820 | Nov 26, 2024 |
| Nov 22, 2024 | XERS Xeris Biopharma Holdings, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -16,843 | $0.00 | $0 | 0 | Nov 26, 2024 |
| Nov 22, 2024 | XERS Xeris Biopharma Holdings, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -2,640 | $0.00 | $0 | 0 | Nov 26, 2024 |
| Jan 31, 2024 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Common Stock | +450,000 | $0.00 | $0 | 1,626,912 | Jan 31, 2024 |
| Nov 20, 2023 | XERS Xeris Biopharma Holdings, Inc. | POpen-market purchase Common Stock | +28,000 | $1.95 | $55k | 1,176,912 | Nov 21, 2023 |
Questions about Steven Pieper
Answered from the filings on this page, as of the latest one.
Is Steven Pieper buying or selling?
In the last 12 months Steven Pieper reported 0 open-market buys worth $0 and 4 open-market sells worth $515k on SEC Form 4; the latest was sold $47k of XERS on Oct 1, 2026. Grants, option exercises and tax withholding are not counted.
How did Steven Pieper's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Steven Pieper has 0.
Where does Steven Pieper file Form 4?
Steven Pieper has filed Form 4 at XERS (Xeris Biopharma Holdings, Inc.) as See Remarks. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.